Review Article
Volume 4 Issue 1 - 2020
Diabetes, Triglycerides and Atherosclerosis
Gerald H Tomkin* and Daphne Owens
Beacon Clinic, Coillancarraig Lodge, Rocky Valley Drive, Kilmacanogue, Co Wicklow, Dublin, Ireland
*Corresponding Author: Gerald H Tomkin, Professor, Beacon Clinic, Coillancarraig Lodge, Rocky Valley Drive, Kilmacanogue, Co Wicklow, Dublin, Ireland.
Received: July 18, 2019; Published: December 31, 2019




Abstract

Raised triglycerides reflect elevated levels of the triglyceride-rich lipoproteins. Triglycerides are a risk factor for cardiovascular disease. Both the apolipoprotein (apo) B48-containing chylomicrons and the apo B100 hepatically derived very low density lipoprotein (VLDL), triglyceride rich particles which, if elevated, confer cardiovascular risk. Fibrates are effective in lowering serum triglycerides and have a very low side effect profile. Trials that have used fibrates to raise high density lipoprotein (HDL) have been unsuccessful as have trials that target patients with normal triglycerides but there is strong evidence that lowering raised triglycerides is beneficial in both primary and secondary cardiovascular prevention. The recent renewed interest in triglycerides as a therapeutic target has resulted in the development of new drugs which show promise.

Keywords: Diabetes; Triglycerides; Cholesterol; Low Density Lipoprotein (LDL); High Density Lipoprotein (HDL); Chylomicrons; Statins; Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

References

  1. Fruchart JC., et al. “The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia”. The American Journal of Cardiology 102.10 (2008): 1K-34K.
  2. Jernberg T., et al. “Cardiovascular risk in post-myocardial infarction patients: nationwide real-world data demonstrate the importance of a long-term perspective”. European Heart Journal 36 (2015): 1163-1170.
  3. Fruchart JC., et al. “The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation”. Cardiovascular Diabetology 18 (2019): 71. 
  4. Emerging Risk Factors Collaboration., et al. “Major lipids, apolipoproteins, and risk of vascular disease”. JAMA 302 (2009): 1993-2000. 
  5. Voight., et al. “Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study”. Lancet 380 (9841): 572-580.
  6. Barter PJ., et al. “Effects of torcetrapib in patients at high risk for coronary events”. The New England Journal of Medicine 357 (2007): 2109-2122. 
  7. Karpe., et al. “Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants”. The Journal of Lipid Research 38.5 (1997): 949-961.
  8. Karpe F., et al. “Clearance of lipoprotein remnant particles in adipose tissue and muscle in humans”. The Journal of Lipid Research 38 (1997): 2335-2343.
  9. Proctor SD., et al. “Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy”. Arteriosclerosis, Thrombosis, and Vascular Biology 24 (2004): 2162-2167. 
  10. Proctor SD and Vine DF, Mamo “Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis”. JC Current Opinion in Lipidology 13 (2002): 461-70. 
  11. Nordestgaard BG., et al. “Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media”. Arteriosclerosis, Thrombosis, and Vascular Biology 15 (1995): 534-542.
  12. ACCORD Study Group., et al. “Effects of combination lipid therapy in type 2 diabetes mellitus”. The New England Journal of Medicine 362 (2010): 1563-1574. 
  13. Borén J., et al. “Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study”. Arteriosclerosis, Thrombosis, and Vascular Biology 35 (2015): 2218-2224.
  14. Khera AV., et al. “Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease”. JAMA 317 (2017): 937-946.
  15. Tancredi M., et al. “Excess Mortality among Persons with Type 2 Diabetes”. The New England Journal of Medicine 373 (2015): 1720-1732. 
  16. Lange T., et al. “Simple unified approach for estimating natural direct and indirect effects”. American Journal of Epidemiology 176 (2012): 190-195. 
  17. Sharif S., et al. “Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort”. Diabetes, Obesity and Metabolism (2019). 
  18. Tomkin GH and Owens D. “The chylomicron: relationship to atherosclerosis”. International Journal of Vascular Medicine 2012 (2012): 784536.
  19. Phillips C., et al. “Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition”. Atherosclerosis 187 (2006): 57-64. 
  20. Balling M., et al. “A third of non fasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals”. Atherosclerosis 286 (2019): 97-104126.
  21. Thorp JM and Waring WS. “Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate”. Nature 194 (1962): 948-949.
  22. Galimberti P and Deffranseschi A. Gazzetta Chimica Italiana (1947): 77-431.
  23. Lalloyer F and Staels B. “Fibrates, glitazones, and peroxisome proliferator-activated receptors”. Arteriosclerosis, Thrombosis, and Vascular Biology 30 (2010): 894-899. 
  24. Duncan LJ., et al. “A three-year trial of atromid therapy in exudative diabetic retinopathy”. Diabetes 17 (1968): 458-467.
  25. Harrold BP., et al. “Double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy”. Diabetes 18 (1969): 285-291.
  26. Matzkies F., et al. “[Procetofen, a new lipid- and urine-acid-reducing substance]”. Fortschritte der Medizin 12.96 (1978): 1939-1941.
  27. da Rosa-Junior NT., et al. “Bezafibrate In Vivo Administration Prevents 3-Methylglutaric Acid-Induced Impairment of Redox Status, Mitochondrial Biogenesis, and Neural Injury in Brain of Developing Rats”. Neurotoxicity Research 35 (2019): 809-822.
  28. Honda A., et al. “Japan PBC Study Group. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients with Primary Biliary Cholangitis”. Hepatology (2019). 
  29. Blane GF and Pinaroli F. “[Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)]”. La Nouvelle presse Médicale 9 (1980): 3737-3746.
  30. Desager JP., et al. “Uricosuric effect of fenofibrate in healthy volunteers”. The Journal of Clinical Pharmacology 20 (1980): 560-564.
  31. Canzler H and Bojanovski D. “Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias”. Artery 8 (1980): 171-178.
  32. Dreyer C., et al. “Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors”. Cell 68 (1992): 879-887.
  33. Issemann I and Green S. “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators”. Nature 347 (1990): 645-650.
  34. Blümcke S., et al. “Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients”. Atherosclerosis 46 (1983): 105-116.
  35. Roberts WC. “Safety of fenofibrate--US and worldwide experience”. Cardiology 76 (1989): 169-179.
  36. Frick MH., et al. “Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease”. The New England Journal of Medicine 317 (1987): 1237-1245.
  37. Elkeles RS., et al. “Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study”. Diabetes Care 21 (1998): 641-648.
  38. Rubins HB., et al. “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group”. The New England Journal of Medicine 341 (1999): 410-418.
  39. ACCORD Study Group., et al. “Effects of combination lipid therapy in type 2 diabetes mellitus”. The New England Journal of Medicine 362 (2010): 1563-1574. 
  40. Elam MB., et al. “ACCORDION Study Investigators. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes”. JAMA Cardiology 2 (2017): 370-380. 
  41. DAIS Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001): 905-910.
  42. Sarwar N., et al. “Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies”. Circulation 115 (2007): 450-458. 
  43. Ivert T., et al. “Cardiovascular events in patients under age fifty with early findings of elevated lipid and glucose levels - The AMORIS study”. PLoS One 23.13 (2018): e0201972.
  44. Mychaleckyj JC., et al. “Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants”. Diabetes Care 35 (2012): 1008-1014. 
  45. Keech A., et al. “FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial”. Lancet 366 (2005): 1849-1861.
  46. Hottelart C., et al. “Fenofibrate increases creatininemia by increasing metabolic production of creatinine”. Nephron 92 (2002): 536-541.
  47. Croyal M., et al. “Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?”. Diabetes and Metabolism 44 (2018): 143-149. 
  48. Davis TM., et al. “Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”. Diabetologia 54 (2011): 280-290. 
  49. Ting RD., et al. “Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study”. Diabetes Care 35 (2012): 218-225.
  50. Rajamani K., et al. “Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial”. Lancet 373 (2009): 1780-1788.
  51. Enger C., et al. “Pharmacoepidemiology safety study of fibrate and statin concomitant therapy”. The American Journal of Cardiology 106 (2010): 1594-601. 
  52. Wang N., et al. “Fenofibrate Exerts Protective Effects in Diabetic Retinopathy via Inhibition of the ANGPTL3 Pathway”. Investigative Ophthalmology and Visual Science 59 (2018): 4210-4217. 
  53. Liu Q., et al. “Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation”. Molecular and Cellular Biochemistry 445 (2018): 105-115. 
  54. Ju HB., et al. “Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients”. Medicine (Baltimore) 96.31 (2017): e7671.
  55. Suzuki K., et al. “Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment”. Arteriosclerosis, Thrombosis, and Vascular Biology 39 (2019): 934-944.
  56. Fujihara Y., et al. “Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL”. Circulation Journal 83 (2019): 1302-1308.
  57. Bhatt DL., et al. Ballantyne CM REDUCE-IT Investigators. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia”. The New England Journal of Medicine 380.1 (2019): 11-22.
  58. Bajaj A., et al. “Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD”. American Journal of Kidney Diseases 73 (2019): 827-836. 
  59. Saeed A., et al. “Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease”. Journal of the American College of Cardiology 72 (2018): 156-169. 
  60. Bowie A., et al. “Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?”. Atherosclerosis. 102 (1993): 63-67.
  61. Dimitriadis E., et al. “Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins”. Diabetologia 39 (1996): 667-676.
  62. Duncan MS., et al. “Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years”. Journal of the American Heart Association 8.11 (2019): e011433. 
  63. Silbernagel G., et al. “LDL Triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study”. Atherosclerosis 282 (2019): 37-44. 
  64. Fruchart JC. “Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease”. Atherosclerosis 205 (2009): 1-8.
  65. Ishibashi S., et al. “Effects of T K-877-04 Study Group. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial”. Atherosclerosis 249 (2016): 36-43. 
  66. Yamashita S., et al. “Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases”. Journal of Atherosclerosis and Thrombosis 26 (2019): 389-402. 
  67. Ishibashi S., et al. “Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial”. Journal of Clinical Lipidology 1 (2018): 173-184.
  68. Araki E., et al. “Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study”. Diabetes, Obesity and Metabolism. 21 (2019): 1737-1744. 
  69. Graham MJ., et al. “Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides”. The New England Journal of Medicine 377 (2017): 222-232. 
  70. Ahmad Z., et al. “Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia”. (2019).
  71. Dewey FE., et al. “Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease”. The New England Journal of Medicine 374 (2016): 1123-33. 
  72. Merkel M., et al. “Accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase”. Journal of Biological Chemistry 280 (2005): 21553-21560. 
  73. Takanashi M., et al. “Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency”. Arteriosclerosis, Thrombosis, and Vascular Biology 39 (2019): 373-386.
  74. Forte TM., et al. “Apolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis”. The Journal of Biomedical Research 30 (2016): 88-93. 
  75. Adiels M., et al. “Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia”. Diabetes, Obesity and Metabolism (2019): 10. 
  76. Li FH., et al. “The silencing of ApoC3 suppresses oxidative stress and inflammatory responses in placenta cells from mice with preeclampsia via inhibition of the NF-κB signaling pathway”. Biomedicine and Pharmacotherapy 107 (2018): 1377-1384.
  77. Arca M., et al. “The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study”. Expert Review of Cardiovascular Therapy 16 (2018): 537-546.
  78. Digenio A., et al. “Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes”. Diabetes Care 39.8 (2016): 1408-1415.
Citation: Gerald H Tomkin and Daphne Owens. “Diabetes, Triglycerides and Atherosclerosis”. EC Nutrition 4.1 (2020): 01-11.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


September Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the September issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before October 06, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.